Genmab — Marts 2017
-
21.000 til A/B i auktionen.
-
-
Har dette link om NICE været bragt før? http://www.fiercepharma.com/pharma/j-j-s-darzalex-gets-cold-shoulder-from-nice-multiple-myeloma
-
Jeg vil bede Rachel om at uddybe problematikken
-
i morgen ved præsentationen på InvestorDagen.
-
Helge - kommer du og Rachel på video på InvestorDagen? Hvis ja, så må du gerne linke indslaget hertil.
-
-
Det gør vi GB. Jeg lægger link ud sidst på ugen.
-
Mange tak
-
-
Janssen's sidste bemærkning til NICE appraisal af Dara kombier:The combination of daratumumab with lenalidomide and dexamethasone is unlikely to be cost-effective, even at zero price as a result of the borderline cost-effectiveness of lenalidomide and dexamethasone. Janssen would like to highlight that as we are not the manufacturer of lenalidomide, we have no influence on the pricing of lenalidomide and would like to discuss this further with NICE as a matter of urgency. This situation only ser
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind